Skip to main content

Table 1 Patient characteristics

From: Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel

 

N (%)

Patients enrolled and fully evaluable

74 (100)

Age, median value (range, IQR)

72 (49–82, 67–77)

ECOG Performance Status

 0–1

55 (74.3)

 2

19 (25.7)

Gleason score

 < 8

14 (22.2)

 ≥8

49 (77.8)

 Unknown/missing

11

Bone mts

72 (97.3)

Visceral mts

11 (15.1)

Liver mts

6 (8.2)

Lymph node mts

42 (57.5)

Presence of pain

25 (36.8)

Previous surgery (radical prostatectomy)

33 (44.6)

Previous radiotherapy (radical radiotherapy)

32 (43.2)

Number of previous treatments

 1

17 (23)

 2

43 (58.1)

 3

14 (18.9)

AR CN

 Normal

40 (54.0)

 Gain

34 (46.0)

Alkaline Phosphatase U/l, median value (range, IQR)

174 (54–965, 101–270)

Lactate Dehydrogenase U/l, median value (range, IQR)

240 (76–1177, 181–345)

Hemoglobin g/l, median value (range, IQR)

12.0 (9.0–15.0, 10.9–13.1)

Neutrophils count, median value (range, IQR)

4150 (840–8730, 3100–5360)

Lymphocytes count, median value (range, IQR)

1495 (90–26,000, 1120–1900)

Platelets count, median value (range, IQR)

236,000 (115,000–719,000, 196,000–295,000)

Serum Albumin g/l, median value (range, IQR)

31.3 (3.7–42.0, 4.0–40.0)

PSA, median value (range, IQR)

54.56 (2.69–5000, 19–175.60)

  1. Abbreviations: IQR interquartile range, ECOG PS Eastern Cooperative Oncology Group performance status, mts metastases, AR androgen receptor CN copy number PSA prostate-specific antigen